Zylet Approval History
- FDA approved: Yes (First approved December 14th, 2004)
- Brand name: Zylet
- Generic name: loteprednol and tobramycin
- Dosage form: Ophthalmic Suspension
- Company: Bausch & Lomb
- Treatment for: Uveitis, Iritis, Conjunctivitis, Bacterial, Keratitis, Cyclitis
Zylet (loteprednol etabonate and tobramycin ophthalmic suspension) a topical anti-inflammatory corticosteroid and antibiotic combination for use in the treatment of inflammatory ocular conditions.
Development History and FDA Approval Process for Zylet
|Dec 14, 2004||Zylet Bausch & Lomb - Treatment for Inflammatory Ocular Conditions|
|Aug 9, 2004||FDA Issues Approvable Letter to Bausch & Lomb for Ophthalmic Anti-inflammatory/Antibiotic Combination Product|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.